# IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

> **NCT04262141** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Terrence J Bradley, MD** · enrollment: 4 (actual)

## Conditions studied

- Essential Thrombocythemia
- Polycythemia Vera

## Interventions

- **DRUG:** IMG-7289

## Key facts

- **NCT ID:** NCT04262141
- **Lead sponsor:** Terrence J Bradley, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-02
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2026-01-07

## Collaborators

- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262141, "IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04262141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*